DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,999,399 B2 Lisowsky Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,999,399 B2 Lisowsky Et Al US0089993.99B2 (12) United States Patent (10) Patent No.: US 8,999,399 B2 Lisowsky et al. (45) Date of Patent: Apr. 7, 2015 (54) COMBINED DISINFECTION AND (58) Field of Classification Search DECONTAMINATION AGENT HAVING None INCREASED EFFECTIVENESS See application file for complete search history. (75) Inventors: Thomas Lisowsky, Monheim (DE); Sven Eggerstedt, Hamburg (DE); (56) References Cited Richard Bloss, Rellingen (DE); U.S. PATENT DOCUMENTS Christiane Ostermeyer, Hamburg (DE); Karlheinz Esser, Monchengladbach 4,477.438 A * 10/1984 Willcockson et al. ........ 424,616 (DE); Frank Birger, Düsseldorf (DE); 4,929,365 A * 5/1990 Clarket al. ................... 210,754 Barbara Krug, Hamburg (DE); Yvonne 6,296,881 B1 10/2001 Hata et al. 2005/0238602 A1* 10/2005 Modak et al. .............. 424.70.11 Feil, Kiel (DE); Kai-Martin Mueller, 2005/0267109 A1* 12/2005 Holz et al. .... ... 514,241 Hamburg (DE); Delphine Haase, 2007/0264353 A1* 1 1/2007 Myntti et al. ................. 424,600 2009/0076084 A1 3/2009 Kruget al. Wentorf (DE) 2010, 0119566 A1 5/2010 Kruget al. Assignee: Bose Chemie GmbH, Hamburg (DE) (73) FOREIGN PATENT DOCUMENTS Notice: (*) Subject to any disclaimer, the term of this DE 19936428 2, 2000 patent is extended or adjusted under 35 DE 29903417 T 2000 U.S.C. 154(b) by 343 days. DE 1991.0355 9, 2000 DE 102005O2O327 11, 2006 (21) Appl. No.: 13/140,436 EP O255875 * 7, 1987 ......... AO1N 35.02 EP O987 300 12/1998 PCT Fled: EP 2O7726O * 7, 2009 ........ CO7D 207/14 (22) Nov. 14, 2009 WO PCT/EP98.03147 12/1998 WO WOO1/28339 4/2001 (86) PCT NO.: PCT/EP2009/008122 WO WO2008/068533 * 6, 2008 ............. AON 59/20 WO WO2008/089822 T 2008 S371 (c)(1), WO WO2009/00399.1 1, 2009 (2), (4) Date: Aug. 25, 2011 WO WO2009,133616 11, 2009 (87) PCT Pub. No.: WO2O10/078883 OTHER PUBLICATIONS PCT Pub. Date: Jul. 15, 2010 Musk, D. J. et al. “Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa' Chemistry & Biol (65) Prior Publication Data ogy, 2005, 12,789-796.* International Search Report, dated Oct. 27, 2010, issued in corre US 2012/O1 O7415A1 May 3, 2012 sponding PCT application PCT/EP2009/008122, 6 pages. PCT International Preliminary Reporton Patentability, dated Jun. 21. (30) Foreign Application Priority Data 2011, issued in corresponding PCT application, PCT/EP2009/ 008122, 10 pages. Dec. 18, 2008 (DE) ......................... 10 2008 O64 481 Wallhaufer, Karl Heinz. Praxis der Sterilisation Desinfektion— Konservierung 3. Aufl. Stuttgart; New York: 1984. Inhaltsverzeichnis (51) Int. C. S.XIX-XXI: ISBN 3-13-416303-p. AOIN3L/02 (2006.01) English translation of Wallhaufer, Karl Heinz. Praxis der Sterilisa AOIN33/12 (2006.01) tion Desinfektion Konservierung 3. Aufl. Stuttgart; New AOIN35/02 (2006.01) York: 1984, ISBN 3-13-416303-p. AOIN3L/08 (2006.01) AOIN3L/10 (2006.01) * cited by examiner AOIN3L/6 (2006.01) AOIN 27/00 (2006.01) Primary Examiner — Mina Haghighatain AOIN 59/00 (2006.01) Assistant Examiner — Erin Hirt AOIN 59/14 (2006.01) (74) Attorney, Agent, or Firm — Nash and Titus, LLC AOIN 37/6 (2006.01) A6 IK3I/045 (2006.01) (57) ABSTRACT A6 IK3 L/047 (2006.01) The invention relates to a novel combined disinfection and A6 IK3I/9 (2006.01) decontamination agent comprising at least one vitamin, at A6 IK3I/4 (2006.01) least one metalion, at least one active-surface compound, and A6 IK3I/II (2006.01) at least one further antimicrobial active Substance. The agent A6IP3I/00 (2006.01) according to the invention Surprisingly shows nearly com AOIN 37/36 (2006.01) plete nucleic acid disintegration in addition to an improved AOIN 59/6 (2006.01) disinfectant effect. The agent can be successfully used as a AOIN 43/08 (2006.01) combined decontamination and disinfection agent for skin, AOIN 59/20 (2006.01) mucous membranes, hands, wounds, and/or hair, and instru (52) U.S. C. ments and Surfaces of all kinds. CPC ......... - - - - - - - A0IN 59/16 (2013.01); A0IN 43/08 (2013.01); A0IN 59/20 (2013.01) 16 Claims, No Drawings US 8,999,399 B2 1. 2 COMBINED DISINFECTION AND nation of animated and inanimate Surfaces. The agent should DECONTAMINATION AGENT HAVING protect Surfaces, i.e., should have good compatibility with INCREASED EFFECTIVENESS materials and be compatible with skin and mucous mem branes. In addition to a reliable disinfection the agent should BACKGROUND OF THE INVENTION display a degradation of nucleic acids which is as complete as possible. This application is a 371 national filing claiming priority The problem is solved in accordance with the invention by from international application PCT/EP2009/008122, filed a disinfection- and decontamination agent containing at least Nov. 14, 2009. This application also claims priority from one vitamin, at least one metalion, at least one surface-active German application 10 2008 064481.1, filed Dec. 18, 2008. 10 compound and at least one antimicrobial active Substance, The entire contents of that international application and that whereby the antimicrobial active substance is selected from German application are incorporated herein by reference. the group consisting of The invention has as Subject matter a disinfection and decontamination agent containing at least one vitamin, at monovalent or multivalent, aliphatic or aromatic and/or least one metalion, at least one Surface-active compound and 15 Substituted alcohols, at least one antimicrobial active Substance. quaternary ammonium compounds, It is necessary in the medicinal area, in the production of aliphatic or aromatic mono- or dialdehydes, food, in test laboratories and in other sensitive areas to kill phenols or phenol derivatives, microorganisms and to remove them as completely as pos aliphatic secondary or tertiary amines, sible. It is known on the one hand to combat the microorgan peroxides or peracids, isms in the form of a disinfection. The term disinfection organic and inorganic acids or their salts, esters or amides, generally denotes the effective, irreversible inactivation, kill guanidines or biguanides, ing or removal of microorganisms. Microorganisms include pyridines or pyrimidines, bacteria, mycobacteria, fungi, yeasts, spores, prions, myco amphoteric active Substance according to the regulation plasms and/or viruses. The latter are removed during the 25 (EC) No. 1451/2007 of the commission of Dec. 4, 2007 disinfection of animated and/or inanimate surfaces, tissues or selected from the group of OOS. amines, n-C10-16-alkyltrimethylene di-, reaction products It turned out in a few areas that a disinfection alone is not from chloroacetic acid (AMPHOLYT 30), Sufficient, since even the killed microorganisms or individual quaternary ammonium compounds, 2-2-(2-carboxy nucleic acid molecules such as DNA and RNA of the micro 30 ethyl)(2-hydroxyethyl)aminoethylamino-2oxyethyl organisms or proteins or other residues can result in further coconut alkyldimethyl-, their hydroxides, their “inner infections directly or by increasing the infectiousness or salts' (Rewoteric QAM 50), resistance of other microorganisms. Therefore, decontamina N-3-(dodecylamino)propylglycine (Amphionic SFB), tion agents are used for the complete elimination of the con isothiazolines, tamination with proteins or nucleic acids. The DNA/RNA 35 ethereal oils or decontamination agents should bring about a nucleic acid a mixture of these. degradation that is as complete as possible for an effective Further embodiments are subject matter of the subclaims decontamination. or are described in the following description. It is therefore necessary in a complete disinfection and decontamination of an animated or inanimate Surface to use 40 DETAILED DESCRIPTION OF THE PREFERRED two agents, namely, a disinfection agent for killing the micro EMBODIMENTS organisms and a decontamination agent for eliminating the remaining residual contamination by nucleic acid molecules, If alcoholic active Substances are used as antimicrobial proteins or other residues. The use of a decontamination agent active Substance, they are preferably monovalent alcohols ensures the efficient decontamination in that the free nucleic 45 Such as methanol, ethanol. 1-propanol, 2-propanol, butanol, acid molecules are modified, denatured or degraded. The chlorobutanol, pentanol or hexanol or a mixture of them, known decontamination agents have the disadvantage that especially preferably ethanol, 1-propanol, 2-propanol, they frequently are chemically aggressive and not absolutely butanol and/or pentanol. The monovalentalcohols are used as safe for health. During the use of aggressive Substances they antimicrobial active substance in a concentration of 1-90%, attack, for example, inanimate Surfaces and result in perma 50 preferably 1.5-80% and especially 2-70 wt.%. Compounds nent damage or discoloration. On animated Surfaces such as with 2 to 80 wt.%, preferably 2 to 40 wt.% and 2 to 30 wt.% hands, skin, mucous membranes many aggressive decon monovalent alcohol proved to be especially suitable. tamination agents cannot be used at all for reasons of health. E.g., propylene glycol, polyethylene glycol, triethylene A less aggressive decontamination agent is known, for glycol, hexyldiglycol, butylene glycol, pentane diol, hexane example from DE 102005 020327 A1. This decontamination 55 diol, heptane diol, octane diol, decane diol, glycerol, prefer Solution consisting of a vitamin, a metal ion and a surface ably as 1,2- or 1,3-diols or hexyldiglycol or mixtures of them active compound displays a good nucleic acid degradation are used, especially preferably propylene
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007
    2007R1451 — EN — 01.09.2013 — 002.001 — 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents ►B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance) (OJ L 325, 11.12.2007, p. 3) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 298/2010 of 9 April 2010 L 90 4 10.4.2010 ►M2 Commission Regulation (EU) No 613/2013 of 25 June 2013 L 173 34 26.6.2013 2007R1451 — EN — 01.09.2013 — 002.001 — 2 ▼B COMMISSION REGULATION (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (Text with EEA relevance) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (1 ), and in particular Article 16(2) thereof, Whereas: (1) Pursuant to Directive 98/8/EC, Member States may only authorise the placing on the market of biocidal products containing active substances included in Annex I, IA or IB to that Directive.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • 84 Annex V Part a Existing Active Substances, Notification of Which
    Annex V TIME PERIODS AND RAPPORTEUR MEMBER STATES FOR THE SUBMISSION OF COMPLETE DOSSIERS FOR EXISTING ACTIVE SUBSTANCES INCLUDED IN THE REVIEW PROGRAMME Part A Existing active substances, notification of which has been accepted, within product types 8 and 14. For any of these active substances within the specified product type, the complete dossiers must be received by the competent authority of the Rapporteur Member State no later than 28 March 2004. Active substances for wood preservatives Rapporteur Member State Name (EINECS and/or others) EC Number CAS Number Cyclohexylhydroxydiazene 1-oxide, potassium salt - 66603-10-9 A Bis[1-cyclohexyl-1,2-di(hydroxy- - 312600-89-8 A .kappa.O)diazeniumato(2-)]-copper 3-phenoxybenzyl-2-(4-ethoxyphenyl)-2- 407-980-2 80844-07-1 A methylpropylether / Etofenprox Formic acid 200-579-1 64-18-6 B Dazomet 208-576-7 533-74-4 B Zinc oxide 215-222-5 1314-13-2 B .alpha.-cyano-3-phenoxybenzyl 3-(2,2-257-842-9 52315-07-8 B dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / Cypermethrin [1alpha(S*),3alpha]-(alpha)-cyano-(3- Plant protection 67375-30-8 B phenoxyphenyl)methyl 3-(2,2-dichloroethenyl)-2.2-product dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / alpha- cypermethrin Propan-2-ol 200-661-7 67-63-0 D L-(+)-lactic acid 201-196-2 79-33-4 D Hexa-2,4-dienoic acid / Sorbic acid 203-768-7 110-44-1 D Calcium dihexa-2,4-dienoate 231-321-6 7492-55-9 D EN 84 EN Active substances for wood preservatives Rapporteur Member State Name (EINECS and/or others) EC Number CAS Number Trimagnesium diphosphide 235-023-7 12057-74-8 D Aluminium phosphide 244-088-0 20859-73-8 D Potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 D .alpha.-cyano-4-fluoro-3-phenoxybenzyl 3-(2,2-269-855-7 68359-37-5 D dichlorovinyl)-2,2- dimethylcyclopropanecarboxylate / Cyfluthrin Margosa ext.
    [Show full text]
  • August 28,2003 Dockets Management Branch
    Marling Address, PO. Box 997, Akron, Ohio 44309-0997 August 28,2003 Dockets Management Branch Food and Drug Administration (HFA-305) 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Dear Sir/Madam: Attached is a hard copy of the comments that were emailed to you on August 27, 2003 regarding the Proposed Rule; Reopening of the Administrative Record for Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Health-Care Antiseptic Drug Products. 68 Fed. Reg. 32003. (May29, 2003). [Docket No.75N-183H]. Thank you, GOJO INDUSTRIES, INC. Michael J. Dolan Research and Development Vice President c74 www.GOJO.com August 27,2003 Mailrng Address: PO. Box 991, Akron, Ohm 44309-0991 Dockets Management Branch Food and Drug Administration (HFA-305) 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Proposed Rule; Reopening of the Administrative Record for Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Health-Care Antiseptic Drug Products. 68 Fed. Reg. 32003. (May 29,2003). [Docket No. 75N-183H] Dear Sir/Madam: GOJO Industries, Inc. hereby submits these comments in response to the Food and Drug Administration’s (FDA’s) reopening of the administrative record regarding the tentative final monograph for Over-the-Counter (OTC) Health-Care Antiseptic Drug Products, 59 Fed. Reg. 3 1402 (June 17, 1994) (1994 TFM). These comments address the safety and efficacy of benzalkonium chloride and benzethonium chloride as active antimicrobial agents in leave-on products (products used without water and that are not rinsed off the skin). SUMMARY: The anticipated finalization of the 1994 TFM will be accompanied by a review of the safety and efficacy of the quaternary ammonium compounds (quats), benzalkonium chloride and benzethonium chloride.
    [Show full text]